Biogen Pays $100M In New Isis Pharma Alliance

Law360, New York (September 9, 2013, 6:50 PM EDT) -- Biogen Idec will pay $100 million upfront to acquire exclusive rights to Isis Pharmaceuticals Inc.'s gene-altering technology, the companies said Monday, in a collaboration that seeks to develop new medications for neurological diseases.

Under the drug development partnership, Carlsbad, Calif., based Isis stands to collect as much as $220 million for every successful drug candidate developed. The six-year collaboration is designed to boost Isis's anti-sense technology, a type of therapy that alters a gene's function in order to compensate for an underlying genetic defect.

"This strategic...
To view the full article, register now.